SMAD3 and neoplasm: Further studies are warranted to compare optimal Tgfbr1 inhibition versus optimal Smad3 inhibition in the LLC tumor model, and whether a Tgfbr1 inhibitor provides any added benefit when given to Smad3-KO mice.